Urine drug screening in the medical setting
- PMID: 11728415
- DOI: 10.1016/s0009-8981(01)00714-8
Urine drug screening in the medical setting
Abstract
Background: The term drug screen is a misnomer since it implies screening for all drugs, which is not possible. Current practice is to limit the testing to the examination of serum for several drugs such as ethanol, acetaminophen, salicylate, and of urine for several specific drugs or classes of drugs. In the emergency setting the screen should be performed in less than one hour. Controversies continue to exist regarding the value of urine drug testing in the medical setting. The reasons for these include the drugs involved, the sample, the methods utilized to perform the tests, and the level of understanding of the physician using the data, all of which are closely related to the other.
Methods: Current automated methods provide rapid results demanded in emergency situations, but are often designed for, or adapted from, workplace testing and are not necessarily optimized for clinical applications. Furthermore, the use of these methods without consideration of the frequency in which the drugs are found in a given area is not cost-effective. The laboratory must understand the limitations of the assays used and provide this information to the physician. Additionally, the laboratory and the physicians using the data must cooperate to determine which drugs are appropriate and necessary to measure for their institution and clinical setting. In doing so it should be remembered that for many drugs, the sample, urine, contains the end product(s) of drug metabolism, not the parent drug. Furthermore, it is necessary to understand the pharmacokinetic parameters of the drug of interest when interpreting data. Finally, while testing for some drugs may not appear cost-effective, the prevention or reduction of morbidity and mortality may offset any laboratory costs.
Conclusions: While the literature is replete with studies concerning new methods and a few regarding physician understanding, there are none that we could find that thoroughly, objectively, and fully addressed the issues of utility and cost-effectiveness.
Similar articles
-
Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).Pain Physician. 2010 Jan-Feb;13(1):E1-E22. Pain Physician. 2010. PMID: 20119473 Clinical Trial.
-
A review of the methods, interpretation, and limitations of the urine drug screen.Orthopedics. 2011 Nov;34(11):877-81. doi: 10.3928/01477447-20110922-22. Orthopedics. 2011. PMID: 22050253
-
Comprehensive Urine Drug Screen by Gas Chromatography/Mass Spectrometry (GC/MS).Methods Mol Biol. 2016;1383:125-31. doi: 10.1007/978-1-4939-3252-8_15. Methods Mol Biol. 2016. PMID: 26660182
-
Clinical Benefits of Direct-to-Definitive Testing for Monitoring Compliance in Pain Management.Pain Physician. 2018 Nov;21(6):E583-E592. Pain Physician. 2018. PMID: 30508989 Review.
-
Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse.Postgrad Med. 2011 Nov;123(6):132-9. doi: 10.3810/pgm.2011.11.2503. Postgrad Med. 2011. PMID: 22104462 Review.
Cited by
-
A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity.BMC Health Serv Res. 2005 Jan 13;5(1):3. doi: 10.1186/1472-6963-5-3. BMC Health Serv Res. 2005. PMID: 15649331 Free PMC article.
-
Urine Drug Screening as Adjunct to History Taking During Intake in Addiction Services.Indian J Psychol Med. 2024 Jan;46(1):88-89. doi: 10.1177/02537176231184598. Epub 2023 Jul 18. Indian J Psychol Med. 2024. PMID: 38524946 Free PMC article. No abstract available.
-
Buyer Beware: Pitfalls in Toxicology Laboratory Testing.Mo Med. 2015 May-Jun;112(3):206-10. Mo Med. 2015. PMID: 26168592 Free PMC article.
-
Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine.BMC Emerg Med. 2009 Apr 28;9:5. doi: 10.1186/1471-227X-9-5. BMC Emerg Med. 2009. PMID: 19400959 Free PMC article.
-
Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.J Cheminform. 2014 May 10;6:22. doi: 10.1186/1758-2946-6-22. eCollection 2014. J Cheminform. 2014. PMID: 24851137 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical